Table 2.
Univariate and multivariate analysis of progression-free survival.
| Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| P-value | HR (95% CI) | P-value | HR (95% CI) | |
| Sex: Male or female | 0.345 | 0.871 (0.654-1.160) | ||
| Age: <45 years or ≥45 years | 0.904 | 0.988 (0.808-1.208) | ||
| Metastasis at presentation: Present or absent | 0.023 | 1.284 (1.035-1.594) | ||
| Liver metastasis: Present or absent | 0.122 | 1.284 (0.936-1.760) | ||
| Lung metastasis: Present or absent | 0.060 | 1.336 (0.987-1.808) | ||
| Pre-treatment S-ALP level: Normal or elevated | <0.001 | 1.602 (1.294-1.985) | <0.001 | 1.656 (1.345-2.040) |
| Post-treatment S-ALP level: Normal or elevated | <0.001 | 2.254 (1.784-2.848) | <0.001 | 2.226 (1.780-2.783) |
| Number of drugs for chemotherapy:Two or three | 0.047 | 0.802 (0.645-0.997) | ||
| Number of involved sites: 1 or ≥1 | 0.704 | 0.928 (0.629-1.367) | ||
| Vertebral metastasis: Present or absent | 0.984 | 1.002 (0.816-1.231) | ||
| Skeletal-related events: Present or absent | 0.899 | 0.980 (0.723-1.329) | ||
HR: hazard ratio; 95% CI: 95% confidence interval.